Back to results
US 5,310,561 AGranted
Antiemetic therapy
AssigneeAlza Corporation
InventorsFrancisco Jao, Hoa T. Huynh, Patrick S. L. Wong
Life of this patent
Estimating the term…
Abstract
A dosage form is disclosed comprising an antiemetic and antinausea drug for treating vomiting and nausea.
Claims5
A dosage form for administering an antiemetic and antinausea drug orally to a patient, wherein the dosage form comprises:
- (a) a wall that surrounds a compartment;
- (b) a composition in the compartment comprising a polymer that expands in the presence of fluid that enters the compartment;
- (c) at least on exit passageway in the wall that connects the exterior with the interior of the dosage form;
- and, wherein the dosage form is characterized by:
- (d) a therapeutic composition in the compartment comprising 1 mg to 400 mg of the antiemetic and antinausea drug ondansetron, which ondansetron is delivered from the dosage form essentially-free of being retained in the exit passageway.
2 more elements
A buccal dosage form for administering ondansetron to the buccal-mucosal tissues of a patient in need of ondansetron therapy, wherein the buccal dosage form comprises:
- (a) a wall comprising a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, and cellulose triacetate which wall surrounds;
- (b) an internal compartment;
- (c) an exit passageway in the wall that connects the buccal-mucosal tissue with the internal compartment;
- (d) a push composition in the compartment;
- comprising a hydroosmotically activated agent, that in the presence of buccal-mucosal fluid that enters the compartment, increases in volume and thereby occupies spaces in the compartment;
- and wherein the buccal dosage form is characterized by:
- (e) a therapeutic composition in the compartment comprising 1 mg to 400 mg of ondansetron, optionally 1 mg to 200 mg of a member selected from the group consisting of benzamine, butyrophenone, phenothiazine, corticosteroid, benzodrazipine, cannabinoid, metoclopramide, haloperidol, droperidol, prochlorperazine, chlorpromazine, dexamethasone, methylprednisolone, lorazepam, nabilone and dronabinol, and a pharmaceutically acceptable carrier for the therapeutic composition.
4 more elements
A subglossal dosage form for administering ondansetron to subglossal ondansetron receptors of a patient in need of ondansetron therapy, wherein the subglossal dosage form comprises:
- (a) a wall comprising a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall surrounds;
- (b) an internal compartment;
- (c) a push composition in the compartment comprising a hydroosmotically activated agent, that in the presence of subglossal fluid that enters the compartment, increases in volume and thereby occupies space in the compartment;
- (d) an exit passageway in the wall that connects the subglossal environment with the internal compartment;
- and wherein the subglossal dosage form is characterized by:
- (e) a therapeutic composition comprising 1 to 400 mg of ondansetron, optionally 1 mg to 200 mg of a member selected from the group consisting of benzamine, butyrophenone, phenothiazine, corticosteroid, benzodiazepine, cannabinoid, metoclopramide, haloperidol, droperidol, prochlorperazine, chlorpromazine, dexamethasone, methylprednisolone, lorazepam, nabilone, and dronabinol, and a pharmaceutically acceptable carrier for the therapeutic composition, and which,
- (f) subglossal dosage form is administered for antiemetic and antinausea therapy in the patient.
4 more elements
Dependencies are inferred from the claim text.